Background
Western equine encephalitis virus (WEEV) belongs to the genus Alphavirus within the Togaviridae family. This virus is originated by recombination of a new world Eastern equine encephalitis virus (EEEV) and the old world Sindbis virus (SINV). [1] [2] [3] WEEV has a positive-strand RNA genome consisting of about 11,700 nucleotides. 1, 4 WEEV, EEEV and the related Venezuelan equine encephalitis virus (VEEV) were first isolated in the 1930s. 2, [5] [6] [7] [8] The enzootic transmission cycle of WEEV includes the vertebrate hosts, birds and mosquitoes. 9 The main mosquito vector of WEEV is Culex tarsalis. 10 These alphaviruses can spread to the human central nervous system (CNS), causing symptoms ranging from mild febrile reactions to encephalitis, often resulting in permanent, fatal neurological damage. The severity of the illness depends on the virus strain, the age of the patient, the dose and the route of infection. 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] WEEV/EEEV and VEEV have caused epidemics in North, Central and South America. An outbreak in Canada in 1941 led to more than 1000 human infections, 21 and a fatal case of human WEEV infection was reported in Uruguay in 2009. 22 For humans, the WEEV case-fatality rate has been estimated at 3 to 7%, and 15 to 30% of convalescent patients develop secondary neurological damage. 9, 23 Mortality rates due to WEEV infection range from 0% to 100% in mice, and the time to death differs between strains. 16, 24, 25 Alphaviruses can be produced in large quantities, are moderately easy to disseminate and are highly infectious as aerosols. 26, 27 VEEV, WEEV and EEEV are therefore considered to be potential biological weapons [28] [29] [30] and are classified as category B bioterrorism agents by the US Centers for Disease Control and Prevention (www.bt.cdc.gov/agent/agentlist-category.asp).
Various active vaccination strategies, based on live-attenuated strains of WEEV, 31 the envelope protein E1, 21 an adenovirusvectored WEEV vaccine, 32, 33 DNA vaccines 34 and recombinant E1/E2 proteins 35 have been evaluated, as well as alternative therapies, such as cationic liposome-DNA complexes (CLDCs) 36 and CLDCs combined with the recombinant WEE E1 protein. 37 Due to the vast geographic distribution of the virus and the limited amount of infections, however, an active vaccination campaign is not realistic. Therefore, a post-exposure therapy is needed. Since "there are no commercial vaccines or anti-WEEV drugs available for humans," 21 the development of human or human-like antibodies for passive vaccination is advised. Two This study describes the development of the first neutralizing antibodies against Western equine encephalitis virus (WeeV), a member of the genus Alphavirus. WeeV is transmitted by mosquitoes and can spread to the human central nervous system, causing symptoms ranging from mild febrile reactions to life-threatening encephalitis. WeeV has been classified as a biological warfare agent by the US Centers for Disease Control and Prevention. No anti-WeeV drugs are currently commercially available. Neutralizing antibodies are useful for the pre-and post-exposure treatment of WeeV infections. In this study, two immune antibody gene libraries were constructed from two macaques immunized with inactivated WeeV. Four antibodies were selected from these libraries and recloned as scFv-Fc, with a human Fc part. These antibodies bound WeeV specifically in eLISA with little or no cross-reaction with other alphaviruses. They were further analyzed by immunohistochemistry. All binders were suitable for the intracellular detection of WeeV particles. Neutralizing activity was determined in vitro. Three of the four antibodies were found to be neutralizing; about 1 ng/mL of the best antibody (Tor69-3A2) neutralized 50% of 5 x 104 TCID50/mL. Due to its human-like nature with a germinality index of 89% (VH) and 91% (VL), the Tor69-3A2 antibody is a promising candidate for future passive vaccine development.
Human-like antibodies neutralizing Western equine encephalitis virus
antibody fragments (scFv) have been generated from the murine IgGs 11D2 38, 39 and 10B5 E7E2 40 for diagnostic purposes. To our knowledge, no neutralizing human or murine anti-WEEV antibodies have been described to date. Non-human primates (NHP) antibody gene libraries and phage display are highly suitable tools for the generation of human-like antibodies for diagnostic and therapeutic purposes. 41, 42 Phage display has been successfully used for the generation of murine, 43 human 44, 45 and human-like 46 antibodies against VEEV. This study concerns the generation and characterization of the first human-like neutralizing antibodies against WEEV.
Results

Animal immunization
Two macaques were immunized with β-PL-inactivated WEEV. The first macaque was immunized twice with a commercial veterinary vaccine (Fluvac Innovator Triple EFT plus EHV, 3EEV) against VEEV, EEEV and WEEV, and then three-times with β-PL-inactivated WEEV, with a final boost 5.5 mo after the initial immunization (referred to as "macaque 1"). The second macaque was immunized with 3EEV and VEEV, 46 then boosted once with WEEV 4 mo after the last VEEV immunization (referred to as "macaque 2"). The immunization scheme is given in Figure 1 . Anti-WEEV antibody titers were evaluated by ELISA. The titration ELISA for "macaque 1" is shown in Figure 2 . The titer reached 1/40960 before the final boost with WEEV, and 1/10249 for the second macaque (data not shown). The immunizaton strategy for "macaque 1" yielded higher anti-WEEV titers than immunzation strategy for "macaque 2" with a series of VEEV immunization followed by one WEEV boost.
Antibody phage display library construction For library cloning, total RNA was isolated from bone marrow lymphocytes after the final boost and reverse-transcribed to generate cDNA. The genes encoding VH and VL (kappa) were cloned into the phagemid pHAL14. 47 Library quality was controlled by colony PCR, which showed over 90% full size inserts in both libraries. The final libraries consisted of 1.3 × 10 7 independent clones for the library derived from "macaque 1," and 2.4 × 10 7 independent clones for the second library "macaque 2." Both libraries were packaged with Hyperphage 48, 49 and satisfactory antibody presentation on phage was confirmed by total phage SDS-PAGE followed by western-blot and anti-pIII immunostaining (data not shown).
Antibody selection and binder gene analysis Antibody selection (panning) was performed on antibodycaptured active WEEV material. Three rounds of panning were performed and 96 soluble scFv antibody clones from the "macaque 1" library (ToR68 antibodies), and 48 antibody clones from the "macaque 2" library (ToR69 antibodies), were produced and analyzed by antigen ELISA. Four binders were identified in the ToR68 panning, and 42 binders were identified in the ToR69 panning. DNA sequencing revealed four unique antibodies from the "macaque 1" library and two unique antibodies from the "macaque 2" library. Two of the six unique binders displayed no specific antigen binding in more stringent assays and were not evaluated further. The corresponding human germline sequences, according to IMGT (www.imgt.org), and the germinality indices of the four validated anti-WEEV antibodies are given in Table 1 . For comparison, the corresponding human germline sequences, the murine germline sequences and the germinality index of the murine anti-WEEV scFv 10B5 40 are given. The selected scFv were recloned into the mammalian expression vector pCMX2.5-hIgG1-Fc-XP 50 to produce the bivalent IgG-like scFv-Fc format. Chinese hamster ovary (CHO) cell lines were established and antibodies were produced in a bioreactor, purified and biotinylated. The most similar human germline genes were identified by IMGT (www.IMGT.org)The germinality index describes the similarity of the antibodies to the corresponding human germline genes identified by IMGT/V-Quest in terms of the percent identity of the VH or VL framework region. 
Binding characteristics
The scFv-Fc versions of the antibodies were analyzed by titration ELISA on active WEEV particles, with a Semliki forest virus (SFV) monoclonal antibody 12/2 51 used as a capture antibody and the scFv-Fc antibodies or SFV12/2 as detection antibodies (Fig. 3) . ToR68-2E9 and ToR68-3G2 showed the most efficient antigen binding, while some background binding was seen for ToR68-2E9 and ToR68-2C3. The determined detection limit was about 6 × 10 3 TCID 50 /mL when using ToR68-2E9.
ELISA on active Alphavirus particles was used to analyze cross-reactions. Alphaviruses were captured in the range of 4 × 10 5 -8 × 10
6 TCID 50 /mL, depending on the individual virus preparation used, and detected with the anti-WEEV antibodies in the scFv-Fc format (Fig. 4) . Due to the different capture antibodies, this assay did not allow a truly quantitative comparison of antigen binding. All four antibodies bound to WEEV. Three of the antibodies were specific for WEEV, but ToR69-3A2 also showed weak binding to the Chikungunya.
All antibodies allowed the detection of WEEV-infected Vero cells by immunohistochemistry (Fig. 5) .
WEEV neutralization Inhibition of WEEV infection of Vero cells by the antibodies was analyzed in vitro using the neutralizing peroxidase-linked antibody (NPLA) assay. 5 × 10 4 TCID 50 /mL WEEV were incubated with a dilution series of the antibodies and, two hours later, 2 × 10 5 Vero cells were infected. The non-neutralizing mAb SFV12/2 was used as a control (Fig. 6) . While ToR68-2C3 did not show neutralizing activity, ToR68-2E9 and ToR68-3G2 antibodies achieved halfmaximal neutralization at about 1-10 μg/mL antibody. Very efficient neutralization was observed with ToR69-3A2 antibody where about 1 ng/mL antibody was sufficient for the halfmaximal neutralization of 5 × 10 4 TCID 50 /mL.
Discussion
WEEV belongs to the new world Alphavirus genus. This virus is transmitted by mosquitoes and can spread to the human CNS, causing symptoms ranging from mild febrile reactions to encephalitis. 2, 4, 9, 16 The post-exposure treatment of WEEV infections using interferon α protects mice only in a short time window of 6 h with limited efficacy. 52 While the protection of mice against WEEV by hyperimmune serum from rabbits has been reported, 53 no neutralizing or protective murine, human or human-like anti-WEEV or anti-EEEV monoclonal antibodies have yet been developed. 54 The situation is different for other Alphaviruses. For passive immunization, human 55 and murine 56 antibody candidates for further therapeutic development have been described for Chikungunya. A panel of neutralizing murine, 26, 57 Figure 2. Anti-WeeV immune responses. Sera were tested by antigen eLISA using supernatants from VrS-purified WeeV-infected Vero cells or non-infected cells (negative control). Bound antibodies were detected by incubation with rabbit anti-monkey IgG conjugated to horseradish peroxidase (HrP). Staining was performed by incubation with 1 μg/mL biotinylated anti-WeeV antibodies, followed by streptavidin-HrP conjugate (1:4,000). As a negative control, we assessed antibody binding to Vero cell culture material.
humanized, [58] [59] [60] [61] human-like monoclonal antibodies from nonhuman primates 46 and one human antibody 44 have been described for VEEV.
The immune antibody phage display libraries employed here were derived from immunized NHP, a technology that has been successfully used for the generation of neutralizing antibodies against other potential biological warfare agents, such as VEEV, 46 anthrax lethal factor, 62 botulinum toxins 63 and ricin. 64 The results of this study confirm that this approach, combined with the conversion to IgG equivalent scFv-Fc antibodies, 50 provides a robust and quick solution for the generation of potential passive vaccination candidates. These phage display immune libraries are an alternative to the use of naive antibody phage display libraries for antibody generation for situations in which serum samples from patients are available or NHP immunization can be justified ethically.
The V-gene sequences of the four validated anti-WEEV NHP antibodies were very similar to the corresponding human V-genes. The germinality index (GI), a value proposed for the initial assessment of immunogenicity in patients, describes the degree of identity of the corresponding FRs to the most similar human germline FR sequences. 65 The GI values of the four scFv ranged from 83.5% to 93.4% for VH and from 73% to 91% for VL. Notably, at 73%, the GI of the light chain of ToR68-2C3 is very low. VBASE2 (www.vbase2.org) identifies the germline gene humIGKV085 as the most identical human gene, a gene that has not yet been assigned to any human kappa subfamily. The GI for this VL would be 91%. All macaque antibodies showed a higher identity to their human counterparts as the murine antibody 10B5 40 with a GI of 65.9%, respectively 68.5%. For comparison, the mean GI values of 100 average functional human scFv antibodies from a naïve scFv library (HAL4/7/8) 47 is 96.6% for VH and 94.8% for VL (unpublished data). Germline humanization of macaque antibodies has been successfully applied to improve the GI. The macaque antibody fragment (35PA 83 ) neutralizing anthrax lethal toxin 65 has been subjected to germline humanization resulting in an increase of its GI value from 87.6% to 97.8%. 66 All antibodies allowed the detection of WEEV in ELISA and IHC after conversion to the scFv-Fc format. This format is functionally equivalent to IgG and may therefore be useful for the diagnostics of WEEV. In this work, two different immunization strategies were employed, with the secondary goal to generate cross reactive antibodies. While one macaque was immunized with the commercial horse vaccine 3EEV first, followed by WEEV only immunizations, the second macaque was immunized first with 3EEV, followed by VEEV immunizations 46 and a final WEEV boost. However, this strategy failed to deliver an antibody with strong cross reactivity to VEEV within the limited number of analyzed clones.
No treatment is currently available for the post-exposure treatment of WEEV infections. The neutralizing antibody ToR69-3A2 against WEEV is a potential candidate for further development into the first passive anti-WEEV vaccine. Its humanlike character should minimize potential immunogenicity and thus side effects of the treatment.
Material and Methods
Ethics statement and animal care
All animal studies presented here were specifically approved by the . Staining was performed with 2 μg/mL biotinylated anti-WeeV scFv-Fc antibodies (200 ng/mL for Tor68-3G2), followed by streptavidin-HrP conjugate (1:4,000). Three eLISA experiments were performed in parallel, with the exception of CKIKV and PIXV for Tor68-3G2. Here, only two eLISA experiments were performed. As negative control, antibody binding to Vero cell culture material was tested. of Laboratory Animals. 68 Animals were kept at constant temperature (22 °C ± -2 °C) and relative humidity (50%), with 12 h of artificial lighting per day. They were housed in individual cages (6 per room) and each had a perch. Animals were fed twice daily, once with dried food and once with fresh fruits and vegetables, and water was provided with the food. Animal technicians observed food intake and general behavior during feeding, and were able to contact a veterinary surgeon if necessary. The veterinary surgeon performed systematic visits to each NHP-room twice weekly. Our environmental enrichment program for non-human primates is limited to games with animal care staff and access to approved toys. The well-being of the animals was monitored by the attending veterinary surgeon. Animals were anaesthetised by an intramuscular injection of 10 mg/kg ketamine (Imalgene®, Merial) before the collection of blood or bone marrow samples. Analgesics were subsequently administered in the form of a single intramuscular injection of 5 mg/kg flunixin (Finadyne®, Schering Plough), if animal technicians suspected that the animal was in pain on the days following an intervention, on the basis of observations of its behavior. No non-human primates were sacrificed during this work.
Cell culture and virus production
All the viruses used in this study are Alphavirus species constituting models of biowarfare agents and belong to the strain collection of the Armed Forces Scientific Institute for Protection Technologies-NBC Protection (WIS). The WEEV strain H160/99 and EEEV strain H178/99 used in this study were received from the National Collection of Pathogenic Viruses (NCPV), UK.
Alphaviruses were propagated in baby hamster kidney or Vero-B4 (African green monkey kidney) cells, at 37 °C, under an atmosphere containing 4% CO 2 , in a biosafety 3 facility, according to standard procedures, as described elsewhere. 26, 61, 69, 70 The cell lines were obtained from the DSMZ-ACC 33 (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).
All viruses were harvested from infected cell monolayers, when 50 to 75% of the cells in the monolayer presented evidence of a viral cytopathic effect (CPE). Virus titers were determined by the 50% tissue culture infective dose (TCID 50 /mL) method, as described by Spearman and Kaerber, or by plaque purification. 71 
Alphavirus purification
Viruses were purified from the supernatants of infected Vero cells by affinity chromatography on Matrex Cellufine Sulfate medium (Virus Recovery System, VRS; Chisso America Inc.) or by isopycnic density gradient centrifugation, as described below. Matrex Cellufine Sulfate medium (VRS) is a cellulose bead medium functionalized with a low concentration of sulfate esters, which operates like a cationexchange resin and has a high affinity for enveloped viruses. It selectively adsorbs complete virus particles and virus coats, according to their charge. Briefly, 50 mL of resin was equilibrated with adsorption buffer (0.01 M phosphate buffer, pH 7.5). Up to 200 mL of virus-containing prefiltered cell culture supernatant was loaded onto the column, which was then was washed twice with 0.01 M phosphate buffer, pH 7.5. Virus particles were then eluted with 1 M NaCl.
Virus particles were purified in two steps. The first step involved ultracentrifugation on a sucrose cushion (20% sucrose), causing low levels of mechanical stress and making it possible Vero cells were infected with WeeV and fixed in formalin, for staining with a 1:5000 dilution of the antibodies (=200 ng/mL for the recombinant antibodies), followed by incubation with streptavidin-HrP conjugate (1:6,000). As positive controls, the anti-WeeV antibody MAB8742 and the anti-alphavirus antibody SFV12/2 were used. As negative control, the streptavidin-HrP conjugate was used without an anti-WeeV antibody.
to concentrate and collect morphologically intact particles by centrifugation at 112,000 × g for 2 to 3 h. The pellet was resuspended in 0.5 to 1 mL phosphate-buffered saline (PBS) and further purified by isopycnic density gradient centrifugation (20 to 60% sucrose) for 18 h at 217,500 × g. The virus-containing fraction was collected and stored at -80 °C for further analysis.
Alphavirus inactivation
All viral antigens were inactivated by incubation with a final concentration of 0.2% β-propionolactone (β-PL, SigmaAldrich). Immediately before use, a 10% β-PL solution was prepared and 0.1 mL of this dilution was incubated with 5 mL of virus-containing cell culture supernatant (pH 8 to 8.5) for 1 h at 4 °C and 4 h at 37 °C, with constant stirring. After 2 and 4 h, the pH of the cell culture supernatant was checked and adjusted if necessary. For complete hydrolysis of the β-PL remaining after inactivation, the supernatant was stored at 4 °C for another 12 to 18 h. The sample was centrifuged for 30 min at 10,006 × g, and viral inactivation was checked by inoculating Vero cells and monitoring for cytopathic effects (CPE) for three to five days.
Animal immunization
A male cynomolgus macaque (Macaca fascicularis) was immunized by intramuscular injection with 100 μL of the commercially available veterinary vaccine Fluvac Innovator Triple EFT plus EHV (Fort Dodge Animal Health). This broad-range vaccine (3EEV) is normally administered to horses to protect them from equine encephalitis caused by the EEE, WEE and VEE viruses. This vaccine also contains inactivated rhinovirus and influenza virus together with tetanus toxoid, to protect horses against equine rhinopneumonitis, influenza and tetanus. One month later, the animal was immunized a second time with this vaccine. The macaque then received an intramuscular injection of 100 μL of VRS-purified β-PL-inactivated WEEV with complete Freund's adjuvant after one month. Two additional injections of 100 μL of antigen preparation were performed, the first with incomplete Freund's adjuvant after one month and the second with complete Freund's adjuvant after 2.5 mo. One week after the final antigen injection, the immune library was generated. A second macaque, previously immunized with 3EEV and VEEV, 46 was immunized with WEEV four months after the final boost with VEEV. Usually, the complete Freund's adjuvant is used for the initial injections then incomplete Freund's adjuvant is used for the subsequent boosts. Here, the final boost was also realized using complete Freund's adjuvant to induce a strong immune response against the targeted antigen, just before the immune library construction. As already observed in other projects, this final boost resulted in high yields of antibody RNA for RT-PCR. The immune library was generated 10 d after WEEV immunization. After each immune boost, serum samples were collected, inactivated by incubation for 20 min at 56 °C and tested for WEEV-specific antibodies by ELISA. For this purpose, VRSpurified culture supernatants from WEEV-infected Vero cells or uninfected cells were immobilized on 96-well microtiter plates (Maxisorp TM , Nunc). For the determination of WEEV-specific antibody titers, serial dilutions of pre-immune serum and of the sera obtained after second, third and fourth immunizations were used. Specifically bound antibodies were detected by incubation with rabbit anti-monkey IgG conjugated to horseradish peroxidase (1:10,000, Sigma-Aldrich) for 30 min at room temperature. Staining was performed with 3-3', 5-5'-tetramethylbenzidine (TMB, Serva) and the reaction stopped with 0.5 M sulfuric acid after 10 min. Absorbance was measured at 450 nm.
Library construction and packaging
The library construction was performed as previously described. 62, 64, 72 In brief, macaque bone marrow lymphocytes were sampled, RNA was isolated and reverse-transcribed into cDNA. The coding regions for the variable regions VLκ and VH were amplified and PCR products were cloned into the pGemT vector (Promega) yielding two antibody gene sublibraries, one encoding heavy chains (Fd fragment) and the other kappa light chains. The pGemT cloned PCR products were reamplified with two macaque oligonucleotide primer sets to introduce restriction sites for two step library cloning. The VH PCR products were first cloned into pHAL14, 47 with the VL PCR fragments inserted in a second cloning step. The library was packaged with hyperphage 48, 49 as previously described. 73 The scFv presentation of the library on the surface of the phage was assessed by SDS-PAGE, western blotting and anti-pIII immunostaining, as previously described.
73
Selection of anti-WEEV antibodies
The selection of recombinant antibodies was performed according to 45 with modifications. Panning was performed in 96-well microtiter plates (MaxiSorp, Nunc). The plates were coated with 3 μg/mL of the capture antibody MAB8742 (anti-WEE antibody, clone 2A2C.3, Merck Millipore) in PBS pH 7.4 74 by incubation overnight at 4 °C. Affinity-purified WEEV (100 μL) was then added to the wells and the plates were incubated for two hours. Non-specific binding was eliminated by incubating antigen-coated wells and wells for the preincubation of the library with affinity-purified supernatant from non-infected Vero cells overnight. The wells for panning and for preincubation were blocked by incubation with 2% (w/v) skim milk powder in PBST (PBS + 0.1% Tween 20; 2% MPBST). Phage particles (2.6 × 10 10 or 8 × 10 10 ) from the anti-WEEV libraries were diluted in PBST containing 1% skim milk, 1% bovine serum albumin (BSA), a nonspecific murine IgG D1-4G2-4-15 75 and the mixture was incubated for 1 h. The supernatant, containing the depleted library, was incubated in the wells with the captured WEEV particles at room temperature for 2 h and the wells were then washed 10 times with PBST. The bound scFv phage particles were eluted with 200 μL trypsin solution (10 μg/mL trypsin in PBS) at 37 °C for 30 min. The supernatant containing eluted scFv phage particles was transferred to a new tube. Eluted scFv phage (10 μL) was used for titration, as previously described. 73 E. coli XL1-Blue MRF' (Agilent; 20 mL of culture in the exponential growth phase; OD 600 = 0.4 -0.5) was infected with the remaining scFv phage, by incubation at 37 °C for 30 min, without shaking. The infected cells were harvested by centrifugation for 10 min at 3220 × g and the pellet was resuspended in 250 μL of 2xTY medium 74 supplemented with 100 mM glucose and 100 μg/mL ampicillin (2xTY-GA), plated on a 15 cm 2xTY agar plate supplemented with 100 mM glucose and 100 μg/mL ampicillin and incubated overnight at 37 °C. The resulting colonies were harvested in 5 mL of 2xTY-GA. The harvested colony suspension (100 μL) was mixed with 30 mL of 2xTY-GA and cultured to an OD 600 of 0.4 to 0.5 at 37 °C, with shaking at 250 rpm. The bacterial suspension (5 mL, ~2.5 × 10 9 bacteria) was infected with 5 × 10 10 M13K07 helper phage (Agilent), incubated at 37 °C for 30 min without shaking, and then for 30 min with shaking at 250 rpm. Infected cells were harvested by centrifugation for 10 min at 3220 × g and the pellet was resuspended in 30 mL of 2xTY supplemented with 100 μg/mL ampicillin and 50 μg/mL kanamycin (2xTY-AK). Antibody phage were produced by incubation for 16 h at 30 °C, with shaking at 250 rpm. Cells were harvested by centrifugation for 10 min at 3220 × g. The supernatant containing the antibody phages (~1 × 10 12 cfu/mL) were used directly, for the next round of panning, or were stored at 4 °C for a few days.
Identification of monoclonal scFv by ELISA Monoclonal scFv were produced as previously described. 73 Plates were coated with 3 μg/mL of the capture antibody MAB8742 (anti-WEE antibody, clone 2A2C.3, Merck Millipore) in PBS pH 7.4 74 by incubation overnight at 4 °C. The VRS-purified WEEV supernatant was then added and plates were blocked with 2%MPBST. For binder identification, supernatants containing monoclonal scFv were incubated in the antigen-coated plates for 1.5 h at room temperature and washed three times with PBST. Bound scFv were detected with the murine mAb Myc1-9E10, which recognizes the C-terminal c-myc tag, and a goat antimouse serum conjugated to horseradish peroxidase (HRP) (Sigma; 1:10,000). Visualization was performed with TMB substrate (BIORAD) and the staining reaction was stopped by adding 100 μL of 0.5 M sulfuric acid. Absorbance at 450 nm and scattered light at 620 nm were measured and the value obtained at 620 nm was subtracted from the value obtained at 450 nm, with a SUNRISE microtiter plate reader (Tecan).
DNA sequencing Antibody V-genes were sequenced by GATC Inc. using the oligonucleotide primer MHLacZ-Pro_f (5' ggctcgtatgttgtgtgg 3'). Bioinformatic analysis was performed using web based resources, including IMGT/V-Quest (www.imgt.org) and VBASE2 (www.vbase2.org).
Construction of stable eukaryotic CHO transfectants and production of scFv-Fc fusions WEEV specific scFv gene fragments were subcloned from the immune library vector pHAL14 into the mammalian expression vector pCMX2.5-hIgG1-Fc 50 using NcoI and NotI restriction sites.
For the stable production of WEEV-specific scFv-Fc fusion proteins, CHO-K1 from the American Type Culture Collection, (ATCC, No. CCL61) were transfected, in the presence of 80 μL Polyfect® (Qiagen GmbH), with 2 to 5 μg of plasmid DNA. Stable clones were selected for resistance to the aminoglycoside antibiotic geniticin (G418). CHO cells were cultured overnight, to 60% to 80% confluence, in 1000 mm 2 petri dishes (Nunc) containing non-selective Dulbecco's Modified Eagle's Medium (DMEM/HAM's F-12), a nutrient mixture supplemented with L-glutamine and sodium bicarbonate, 10% (v/v) fetal calf serum (FCS) and 1% (w/v) penicillin and 1% (w/v) streptomycin (PAA), at 37 °C, under an atmosphere containing 4% CO 2 . DNA-lipid complex formation was supported by the prior incubation of plasmid DNA and Polyfect® in serum -and antibiotic-free medium for 10 min at room temperature before transfection. During lipid-DNA complex formation, the CHO-K1 cells were washed with PBS. Medium (7 mL) supplemented with FCS and penicillin/streptomycin was then added to the complex. The mixture was then immediately mixed with the washed cells by gently swirling. Cells were incubated with the transfection complex for 3 h. The medium was then removed and replaced with fresh non-selective DMEM/HAM's F-12 medium containing 10% (v/v) FCS and 1% (w/v) penicillin/streptomycin before incubation of the plates overnight at 37 °C, under an atmosphere containing 4% CO 2 . The medium was changed again one day after transfection. The transfected cells were detached by treatment with trypsin and dispensed at a dilution of 1:50 or 1:100 in new petri dishes, on selective medium also containing 700 mg/mL G418. The medium was changed every three to four days and the first stable G418-resistant clones were observed about three weeks after transfection. Four and five weeks after transfection, single clones were isolated and cultured on 24-well plates (Nunc). As productivity varies between clones, the production of WEEV-specific scFv-Fc fusions was assessed in the supernatants of 24 clones, by ELISA, as described above. Two of the CHO-K1-clones with the highest antibody production levels were then cultured in suspension, in DMEM/HAM's F-12 medium containing 10% (v/v) (FCS), 1% (w/v) penicillin/ streptomycin and 700 mg/mL G418, in a miniPerm bioreactor (Sarstedt), at 37 °C, under an atmosphere containing 4% CO 2 . The culture supernatant was harvested twice weekly and replaced with fresh medium. Recombinant fusion proteins were purified by immunoaffinity chromatography on goat anti-human (GAH) Sepharose.
Biotinylation of mAbs and scFc-Fv fusions
The mAb or scFc-Fv antibodies (1 to 2 mg) were dissolved in sodium bicarbonate buffer, pH 8.5, and incubated with an aliquot of the biotin N-hydroxysuccinimide ester (long arm, watersoluble; Vector laboratories) corresponding to 1/10 the weight of the protein to be labeled. The mixture was incubated for 2 h at room temperature. The reaction was stopped by the addition of 10 mg glycine and the unreacted biotin was removed by gel filtration with PD-10 desalting columns containing Sephadex G25 (GE Healthcare), in accordance with the manufacturer's protocol.
Crossreactivity ELISA Plates were coated with 3 μg/mL capture antibody SFV12/2 (anti-WEEV, anti -Sindbis virus, anti-SFV and Chikungunya virus), 76 mAb Pix c/t 6/2 (anti-Pixuna virus) (Greiser-Wilke, unpublished) or mAb VEE WIS1 (anti-VEEV) 46 in PBS pH 7.4, 74 by incubation overnight at 4 °C. The VRS-purified virus supernatant was then added and plates were blocked by incubation with 2%MPBST. The Alphaviruses analyzed were WEEV (4 × 10 5 TCID 50 /mL), EEEV (6 × 10 5 TCID 50 /mL), VEEV (8 × 10 6 TCID 50 /mL), SINV (8 × 10 5 TCID 50 /mL), SFV (2.5 × 10 6 TCID 50 /mL), Chikungunya virus (CHIKV, 7 × 10 5 TCID 50 /mL) and Pixuna virus (PIXV, 8 × 10 5 TCID 50 /mL). Vero cell culture material was used as a control. The captured Alphaviruses were detected with 2 μg/mL (200 ng/mL for ToR68-3G2) biotinylated anti-WEEV antibodies, followed by incubation with streptavidin-horseradish peroxidase conjugate (PSA, GE Healthcare) (1:6000 in PBS) as described above.
Immunohistochemistry Vero cells (2 × 10 5 cells/mL) were grown in 96-well microtiter plates for 24 h and infected with serial 10-fold dilutions of WEEV strain 160/99. Non-infected Vero cells were used as a negative control. WEEV-infected cells were stained specifically with biotinylated scFv-Fc ToR68-2C3, ToR68-2E9, ToR68-3G2, ToR69-3A2, mAb SFV12/2 or mAb 8742 (anti-WEEV antibody clone 2A2C.3, Merck Millipore) as a positive control. One day post infection (pi), the infected cells were fixed by incubation with 3% formalin in PBS for 3 h at 4 °C. The fixed samples were then incubated with their cognate antibodies in either a 1:5,000 or 1:10,000 dilution in PBSF-T (PBS plus 1% FCS plus 0.1% Tween 20) for 1 h in a humid chamber at 37 °C. The fixed cells were washed three times in PBS-T (PBS plus 0.01% Tween 20) and incubated for 30 min with streptavidin-horseradish peroxidase conjugate (PSA, GE Healthcare) diluted 1:6,000 in PBS-FT. The cells were thoroughly washed and the infected cells were visualized under a microscope following incubation with the precipitating colorimetric peroxidase substrate TMB for 10 min. The staining reaction was stopped by rinsing the plates with Millipore-purified water.
Neutralizing peroxidase linked antibody assay (NPLA) The NPLA assay for scFv-Fc fusions and complete IgG antibodies was performed by a modified version of the procedure described by Jensen. 77 All assays were performed in 96-well microtiter plates, with Vero cells used as the host for infection. A dilution series (50 μL) of scFv-Fc fusions or mAbs were incubated with an equal volume of WEE virus strain 160/99, with a TCID 50 /mL of 5 × 10 4 , for 2 h at 37 °C, in 96-well plates. Following this incubation, 100 μL of freshly trypsintreated Vero cells, at a density of 2 × 10 5 cells/mL, was mixed with the antibody virus mixture. As a positive control for infection, virus samples, not previously incubated with antibody, and virus samples previously incubated with WEEV-specific antibodies with no neutralizing activity, such as mAb 8742 or mAb SFV12/2, were used. Non-infected Vero cells were used as a negative control. Cell monolayers were fixed 20 to 24 h post infection, by incubation with 3% formalin in PBS for 2 h at 4 °C. The monolayers were washed with PBS-T, overlaid with 100 μL of a 1:5,000 dilution of the WEEV-specific biotinylated mAb SFV 12/2 and incubated for 90 min at room temperature. Bound biotinylated mAbs were detected by incubation with streptavidin-HRP conjugate (GE Healthcare, 1:4,000) as described above. An Olympus CK2 inverted microscope (Olympus) was used for bright field microscopy.
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